- Immunoassay-gamma counters, essential for detecting and quantifying radioisotopes in biological samples, are increasingly critical in clinical diagnostics, pharmaceutical research, and endocrinology due to their precision, sensitivity, and automation capabilities
- The rising demand for immunoassay-gamma counters is primarily driven by the growing prevalence of chronic diseases, increased use of radioimmunoassays in hormone and cancer marker detection, and advancements in nuclear medicine technologies
- North America dominated the immunoassay-gamma counters market with the largest revenue share of 41.8% in 2024, attributed to its advanced healthcare infrastructure, high research funding, and a strong presence of key manufacturers, with the U.S. showing significant uptake in academic and diagnostic laboratories driven by increasing investments in life sciences
- Asia-Pacific is expected to be the fastest growing region in the immunoassay-gamma counters market during the forecast period due to expanding healthcare systems, rising diagnostic awareness, and increased investments in laboratory infrastructure
- The automated gamma counters segment dominated the market with a market share of 46.1% in 2024, owing to their time efficiency, reduced human error, and enhanced throughput in clinical and research environments
